Home > Insider Trading > Filing (0000914190-21-000321)

Filing Details

Accession Number:: 0000914190-21-000321
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-02 16:48:36
Reporting Period:: 2021-08-31

Accepted Time:: 2021-09-02 16:48:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
842023	Bio-Techne Corp	TECH	Biological Products, (No Disgnostic Substances) (2836)	411427402

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443851	S. Brenda Furlow	614 Mckinley Place Ne Minneapolis MN 55413	Svp - General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-08-31	5,000	$125.05	12,620	No	4	M	Direct
Common Stock	Disposition	2021-08-31	323	$503.24	12,297	No	4	S	Direct
Common Stock	Disposition	2021-08-31	1,569	$505.26	10,728	No	4	S	Direct
Common Stock	Disposition	2021-08-31	3,108	$506.12	7,620	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2021-08-31	5,000	$0.00	5,000	$125.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,374		2024-08-09	No	4	M	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options (Right to Buy)	$108.49		2022-08-07	921	921	Direct
Common Stock	Stock Options (Right to Buy)	$177.32		2025-08-08	7,339	7,339	Direct
Common Stock	Stock Options (Right to Buy)	$177.32		2025-08-08	9,786	9,786	Direct
Common Stock	Restricted Stock Units	$0.00			1,969	1,969	Direct
Common Stock	Stock Options (Right to Buy)	$190.41		2026-08-07	9,968	9,968	Direct
Common Stock	Stock Options (Right to Buy)	$190.41		2026-08-07	13,290	13,290	Direct
Common Stock	Restricted Stock Units	$0.00			1,679	1,679	Direct
Common Stock	Stock Options (Right to Buy)	$267.87		2027-08-05	7,492	7,492	Direct
Common Stock	Stock Options (Right to Buy)	$267.87		2027-08-05	9,990	9,990	Direct
Common Stock	Stock Options (Right to Buy)	$267.87		2027-08-05	8,325	8,325	Direct
Common Stock	Stock Options (Right to Buy)	$267.87		2027-08-05	8,325	8,325	Direct
Common Stock	Stock Options (Right to Buy)	$372.44	2022-08-31	2028-03-01	10,997	10,997	Direct
Common Stock	Restricted Stock Units	$0.00			1,167	1,167	Direct
Common Stock	Stock Options (Right to Buy)	$481.82		2028-08-06	4,560	4,560	Direct
Common Stock	Stock Options (Right to Buy)	$481.82		2028-08-06	6,080	6,080	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-08-07	921	921	Direct
2025-08-08	7,339	7,339	Direct
2025-08-08	9,786	9,786	Direct
	1,969	1,969	Direct
2026-08-07	9,968	9,968	Direct
2026-08-07	13,290	13,290	Direct
	1,679	1,679	Direct
2027-08-05	7,492	7,492	Direct
2027-08-05	9,990	9,990	Direct
2027-08-05	8,325	8,325	Direct
2027-08-05	8,325	8,325	Direct
2028-03-01	10,997	10,997	Direct
	1,167	1,167	Direct
2028-08-06	4,560	4,560	Direct
2028-08-06	6,080	6,080	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.06 to $503.43, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.63 to $505.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.92 to $506.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Fully exercisable.
Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 2,498 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 2,497 shares vest on each of 8/5/2023 and 8/5/2024.
Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 1,520 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.